Literature DB >> 20412782

Combined albendazole and amphotericin B against Echinococcus multilocularis in vitro.

Stefan Reuter1, Taro Beisler, Peter Kern.   

Abstract

Benzimidazoles, namely albendazole (ABZ) and mebendazole, are the only drugs licensed for the treatment of inoperable alveolar echinococcosis. In addition, amphotericin B (AMB) has shown effect against Echinococcus multilocularis as salvage treatment in humans. Both benzimidazoles and AMB are only parasitostatic against E. multilocularis and toxicity may limit long-term use. In the present study we examined the effect of combined treatment between ABZ and AMB on E. multilocularis larvae in an in vitro model. Vesicles were grown in a tissue culture model of metacestodes and hepatocytes. Drugs were added to the culture and the destructive effect on the vesicles was visually observed. Sequential application of ABZ and AMB yielded effective destruction of vesicles which was faster than the application of AMB alone. However, simultaneous application of ABZ and AMB had an inhibitory effect on vesicle destruction. After discontinuation of drug application, regrowth of vesicles occurred, hereby proving the parasitostatic effect of combined treatment against E. multilocularis larvae. Due to an inhibitory effect between ABZ and AMB against E. multilocularis larvae, we discourage from the simultaneous application of both drugs. If our in vitro results hold true in vivo, sequential application of ABZ and AMB would be an effective means for long-term suppression of larval growth. Long-term tolerance of both drugs could be improved by a reduction of side effects. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412782     DOI: 10.1016/j.actatropica.2010.04.009

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  6 in total

1.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

2.  In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis.

Authors:  David Richter; Joachim Richter; Beate Grüner; Kathrin Kranz; Juliane Franz; Peter Kern
Journal:  Parasitol Res       Date:  2013-02-28       Impact factor: 2.289

3.  In vitro and in vivo activities of dicationic diguanidino compounds against Echinococcus multilocularis metacestodes.

Authors:  Tatiana Küster; Nadja Kriegel; David W Boykin; Chad E Stephens; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

4.  Repurposing of an old drug: In vitro and in vivo efficacies of buparvaquone against Echinococcus multilocularis.

Authors:  Reto Rufener; Luca Dick; Laura D'Ascoli; Dominic Ritler; Amani Hizem; Timothy N C Wells; Andrew Hemphill; Britta Lundström-Stadelmann
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-10-31       Impact factor: 4.077

5.  2-Deoxy-D-glucose and combined 2-Deoxy-D-glucose/albendazole exhibit therapeutic efficacy against Echinococcus granulosus protoscoleces and experimental alveolar echinococcosis.

Authors:  Qi Xin; Wei Lv; Yunxi Xu; Yumei Luo; Caifang Zhao; Bichen Wang; Miaomiao Yuan; Huanping Li; Xiaoxia Song; Tao Jing
Journal:  PLoS Negl Trop Dis       Date:  2022-07-18

6.  Salvage Therapy for Alveolar Echinococcosis-A Case Series.

Authors:  Sanne Burkert; Lynn Peters; Johannes Bloehdorn; Beate Grüner
Journal:  Pathogens       Date:  2022-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.